

# 1 **Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for** 2 **point of care clinical application**

3 Suying Lu <sup>1-3</sup>, David Duplat <sup>4</sup>, Paula Benitez-Bolivar <sup>4</sup>, Cielo León <sup>4</sup>, Stephany D Villota <sup>5</sup>, Eliana Veloz-  
4 Villavicencio <sup>5</sup>, Valentina Arévalo <sup>5</sup>, Katariina Jaenes <sup>6</sup>, Yuxiu Guo <sup>7</sup>, Seray Cicek <sup>7</sup>, Lucas Robinson <sup>8</sup>,  
5 Philippos Peidis <sup>1-3</sup>, Joel D Pearson <sup>1-3</sup>, Jim Woodgett <sup>1,9</sup>, Tony Mazzulli <sup>2,10</sup>, Patricio Ponce <sup>5</sup>, Silvia  
6 Restrepo <sup>11</sup>, John M González <sup>12</sup>, Adriana Bernal <sup>13</sup>, Marcela Guevara-Suarez <sup>14</sup>, Keith Pardee <sup>6,7,15</sup>,  
7 Varsovia E Cevallos <sup>5</sup>, Camila González <sup>4</sup>, Rod Bremner <sup>1-3\*</sup>

8  
9 <sup>1</sup> Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System, Toronto, M5G, 1X5,  
10 ON, Canada

11 <sup>2</sup> Department of Laboratory Medicine and Pathobiology,

12 <sup>3</sup> Department of Ophthalmology and Vision Science, University of Toronto, Toronto, M5T 3A9, ON,  
13 Canada

14 <sup>4</sup> Centro de Investigaciones en Microbiología y Parasitología Tropical (CIMPAT), Department of  
15 Biological Sciences, Universidad de los Andes, Bogotá, Colombia

16 <sup>5</sup> Centro de Investigación en Enfermedades Infecciosas y Vectoriales (CIREV), Instituto Nacional de  
17 Investigación en Salud Pública, Quito, Ecuador.

18 <sup>6</sup> Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada

19 <sup>7</sup> LSK Technologies Inc., 151 Charles St W, Kitchener, ON N2G 1H6, Canada

20 <sup>8</sup> Velocity, University of Waterloo, Kitchener, ON, N2G 1H6, Canada

21 <sup>9</sup> Department of Medical Biophysics, University of Toronto, Toronto, Canada

22 <sup>10</sup> Department of Microbiology, Sinai Health System/University Health Network, Toronto, Canada

23 <sup>11</sup> Department of Food and Chemical Engineering, Universidad de los Andes, Bogotá, Colombia

24 <sup>12</sup> Grupo de Ciencias Básicas Médicas, School of Medicine, Universidad de los Andes, Bogotá, Colombia

25 <sup>13</sup> Laboratory of Molecular Interactions of Agricultural Microbes (LIMMA), Department of Biological  
26 Sciences, Universidad de Los Andes, Bogotá, Colombia

27 <sup>14</sup> Applied genomics research group, Vicerrectoría de Investigación y Creación, Universidad de los Andes,  
28 Bogotá, Colombia

29 <sup>15</sup> Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, M5S 3G8, ON,  
30 Canada

31

32 \*Corresponding Author

33 Email: [bremner@lunenfeld.ca](mailto:bremner@lunenfeld.ca)

## 34 **Abstract**

35 Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests  
36 remain vital to constrain the COVID-19 pandemic. Affordable, point-of-care (PoC) tests allow  
37 rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal  
38 amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in  
39 low/medium resource settings. Here, we optimized RT-LAMP for SARS-CoV-2 and human  $\beta$ -  
40 actin, and tested clinical samples in multiple countries. “TTTT” linker primers did not improve  
41 performance, and while guanidine hydrochloride, betaine and/or Igepal-CA-630 enhanced  
42 detection of synthetic RNA, only the latter two improved direct assays on nasopharygeal  
43 samples. With extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as  
44 RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI: 67.6% -  
45 100%) for those with RT-qPCR Ct values  $\leq 25$ , and 80% (95% CI: 58.4% - 91.9%) for those  
46 with  $25 < Ct \leq 27.2$ . Highly infectious, high titer cases were also detected in Colombian and  
47 Ecuadorian labs. We further demonstrate the utility of replacing thermocyclers with a portable  
48 PoC device (FluoroPLUM). These combined PoC molecular and hardware tools may help to  
49 limit community transmission of SARS-CoV-2.

50

## 51 **Introduction**

52 With continuing waves of coronavirus disease 2019 (COVID-19) around the world, there  
53 has been sustained focus on testing to mitigate and suppress spread of the disease [1]. Limited  
54 vaccination and the emergence of new variants [2], most recently Omicron [3], exacerbate

55 recurrent viral surges. Viral shedding in COVID-19 patients peaks on or before symptom onset,  
56 and contact tracing and quarantine should be done at a crucial temporal window 2 to 3 days  
57 before demonstration of symptoms [4,5], although the exact timing to obtain reliable results is  
58 debated [6,7]. Although current gold-standard quantitative real-time polymerase chain reaction  
59 (qPCR) assays have sensitive analytical limits of detection (LoD), they are generally performed  
60 in sophisticated detection centers with high cost and long turnaround times [8]. Computer  
61 modelling studies based on the pattern of viral load kinetics show that effective community  
62 control of transmission depends more on testing frequency and shorter turnaround times, than  
63 analytical LoD [8]. Further, reducing the barriers to testing may also provide significant benefit  
64 in settings where point-of-need applications are time sensitive and infrastructure is limited (e.g.  
65 school testing and travel). Viral load correlates negatively with cycle threshold (Ct) values and  
66 positively with infectivity[9]. A few reports suggested that COVID-19 patients with Ct values  $\leq$   
67 25 are more likely to be infectious while patients with Ct values above 33-34 are not contagious  
68 [10–12]. Modelling further shows that routine testing substantially reduces risk of COVID-19  
69 outbreaks in high-risk healthcare environments, and may need to be as frequent as twice weekly  
70 [13]. Effective COVID-19 containment demands point-of-care (PoC) tests with short turnaround  
71 time, low cost and high accessibility [14]. Indeed, many rapid PoC antigen and molecular-based  
72 tests for diagnosis of SARS-CoV-2 infection have been developed with a wide range of detection  
73 sensitivity and overall high specificity [15]. Some of these tests are approved by regulatory  
74 agencies and commercially available [15]. However, the high cost of the rapid antigen tests and  
75 the requirement of specialized automated instruments for the molecular-based tests [15] limits  
76 accessibility to broad communities.

77 Reverse transcription loop-mediated isothermal amplification (RT-LAMP) can be  
78 performed in a low-resource setting by merely heating the samples and reagents in a single  
79 reaction tube at one constant temperature, and diagnosis is available within 30 minutes [16]. RT-  
80 LAMP has clear advantages over RT-PCR as a PoC test, and it has been applied to diagnose  
81 several viral diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East  
82 Respiratory Syndrome (MERS), among others [16]. The scientific community has applied RT-  
83 LAMP to detect SARS-CoV-2 in different kinds of samples, using different primers and  
84 experimental readouts. In most of those studies, viral detection required purified RNA or sample  
85 treatment, and generated variable detection efficiencies [16]. Among seven isothermal tests with  
86 Emergency Use Approval (EUA), the LoDs vary up to 50-fold, and are much less sensitive than  
87 those of RT-PCR [17]. Recent studies have utilized RT-LAMP on direct patient samples without  
88 any RNA purification [18–22], proving feasibility of this approach. However, these studies did  
89 not examine assay robustness in different settings, particularly in low resource countries where  
90 reagent availability can be a major roadblock. Here, we set out to develop an optimized RT-  
91 LAMP assay and assess feasibility and robustness in different low resource countries.

92 Using a commercially available RT-LAMP kit, we performed systematic primer  
93 optimization, and further improved sensitivity with primer multiplexing, and various additives.  
94 Using purified RNA as the template, the optimized RT-LAMP assay has similar sensitivity and  
95 specificity to commercial RT-PCR kits used widely in the clinic. Direct RT-LAMP with raw  
96 clinical samples was less efficient, but detected high titer samples from patients predicted to be  
97 infectious with high specificity and sensitivity. At a stringent cutoff of 100% specificity (no  
98 false positives) as FDA recommended [23], labs using the RT-LAMP assay in Canada, Colombia  
99 and Ecuador displayed a range of sensitivities, but each could detect highly infectious disease.

100 Finally, using a PoC instrument that enables de-centralized deployment of the RT-LAMP assay,  
 101 we describe the application of this test on raw unpurified samples. This direct RT-LAMP  
 102 strategy reduces the barrier to establishing testing capacity by overcoming the need for  
 103 laboratory infrastructure for RNA extraction or specialized thermocycling and optical monitoring  
 104 equipment. This detection method has potential as a PoC test to screen individuals with high  
 105 viral loads and mitigate viral transmission.

106

## 107 **Materials and Methods**

### 108 **Oligos**

109 All oligos (Table 1) were ordered from IDT and dissolved with DNase/RNase-free water  
 110 at 100µM concentration. The purification method for F3, B3, LF and LB was standard desalting,  
 111 and the purification method for FIP and BIP was HPLC. Oligos for each primer set were  
 112 combined to make a 10X mix based on required concentrations.

113 **Table 1. Primer sets that were optimized for RT-LAMP**

Primer name	Primer sequence	Sequence targeted	References	Phase
ORF1a-C-F3	CTGCACCTCATGGTCATGTT	498-517 in GeneBank: MT007544.1	Zhang Y <i>et al.</i> [24]	1 <sup>a</sup>
ORF1a-C-B3	GATCAGTGCCAAGCTCGTC	704-722 in GeneBank: MT007544.1		
ORF1a-C-LF	ACCACTACGACCGTACTGAAT	ORF1a of SARS-CoV-2		
ORF1a-C-LB	TTCGTAAGAACGGTAATAAAGGAGC			
ORF1a-C-FIP	GAGGGACAAGGACACCAAGTGTGGTAGCAGAACTCGAAGGC			
ORF1a-C-BIP	CCAGTGGCTTACCGCAAGGTTTTAGATCGGCGCCGTAAC			
ORF1a-C-TFIP	GAGGGACAAGGACACCAAGTGT <b>TTTT</b> TGGTAGCAGAACTCGAAGGC			
ORF1a-C-TBIP	CCAGTGGCTTACCGCAAGGTT <b>TTTT</b> TTAGATCGGCGCCGTAAC			
As1_F3	CGGTGGACAAATTGTAC	2245-2262 in GeneBank: MT007544.1	Rabe BA <i>et al.</i> [25]	1 <sup>a</sup>
As1_B3	CTTCTCTGGATTTAACACTT	2420-2441 in GeneBank: MT007544.1		

As1_LF	TTACAAGCTTAAAGAATGTCTGAACACT	ORF1a of SARS-CoV-2		
As1_LB	TTGAATTTAGGTGAAACATTTGTCCACG			
As1e_FIP	TCAGCACACAAAGCCAAAAATTTATTTTTCTGTGCAAAGGAAATTAAGGAG			
As1e_BIP	TATTGGTGGAGCTAAACTTAAAGCCTTTTTCTGTACAATCCCTTTGAGTG			
ORF1a-F3	TCCAGATGAGGATGAAGAAGA	3043-3063 in GeneBank: MT007544.1	Lamb LE <i>et al.</i> [26]	1 <sup>a</sup> 2 <sup>b</sup> 3 <sup>c</sup> 4 <sup>d</sup> 5
ORF1a-B3	AGTCTGAACAACTGGTGAAG	3311-3331 in GeneBank: MT007544.1		
ORF1a-LF	CTCATATTGAGTTGATGGCTCA	ORF1a of SARS-CoV-2		
ORF1a-LB	ACAAACTGTTGGTCAACAAGAC			
ORF1a-FIP	AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAG			
ORF1a-BIP	TCAACCTGAAGAAGAGCAAGAAGCTGATTGTCCTCACTGCC			
ORF1a-TFIP	AGAGCAGCAGAAGTGGCATTTTAGGTGATTGTGAAGAAGAAGAG			
ORF1a-TBIP	TCAACCTGAAGAAGAGCAAGAATTTTCTGATTGTCCTCACTGCC			
GeneE1-F3	TGAGTACGAATTATGTACTCAT	26232-26254 in GeneBank: MT007544.1	Zhang Y <i>et al.</i> [27]	1 <sup>a</sup> 2 <sup>b</sup> 3 <sup>c</sup> 4 <sup>d</sup> 5
GeneE1-B3	TTCAGATTTTAAACAGGAGT	26420-26441 in GeneBank: MT007544.1		
GeneE1-LF	CGCTATTAECTATTAACG	Gene E of SARS-CoV-2		
GeneE1-LB	GCGCTTCGATTGTGTGCGT			
GeneE1-FIP	ACCACGAAAGCAAGAAAAGAAAGTTTCGTTTCGGAAGAGACAG			
GeneE1-BIP	TTGCTAGTTACACTAGCCATCCTTAGGTTTTACAAGACTCACGT			
GeneE1-TFIP	ACCACGAAAGCAAGAAAAGAAAGTTTTTCGTTTCGGAAGAGACAG			
GeneE1-TBIP	TTGCTAGTTACACTAGCCATCCTTATTTGGTTTTACAAGACTCACGT			
GeneN-A-F3	TGGCTACTACCGAAGAGCT	28525-28543 in GeneBank: MT007544.1	Zhang Y <i>et al.</i> [24]	1 <sup>a</sup>
GeneN-A-B3	TGCAGCATTGTTAGCAGGAT	28722-28741 in GeneBank: MT007544.1		
GeneN-A-LF	GGACTGAGATCTTTACATTTACCGT	Gene N of SARS-CoV-2		
GeneN-A-LB	ACTGAGGGAGCCTGAATACA			
GeneN-A-FIP	TCTGGCCCAGTTCCTAGGTAGTCCAGACGAATTCGTGGTGG			
GeneN-A-BIP	AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT			
GeneN-A-TFIP	TCTGGCCCAGTTCCTAGGTAGTTTTCCAGACGAATTCGTGGTGG			
GeneN-A-TBIP	AGACGGCATCATATGGGTTGCATTTTCGGGTGCCAATGTGATCT			
N-gene-F3	AACACAAGCTTTCGGCAG	29083-29100 in GeneBank: MT007544.1	Broughton JP <i>et al.</i> [28]	1 <sup>a</sup> 2 <sup>b</sup>
N-gene-B3	GAAATTTGGATCTTTGTCAATCC	29290-29311 in GeneBank: MT007544.1		
N-gene-LF	TTCTTGCTGATTAGTTC	Gene N of SARS-CoV-2		

N-gene-LB	ACCTTCGGGAACGTGGTT			
N-gene-FIP	TGCGGCCAATGTTTGTAAATCAGCCAAGGAAATTTGGGGAC			
N-gene-BIP	CGCATTGGCATGGAAGTCACTTTGATGGCACCTGTGTAG			
N-gene-TFIP	CGCATTGGCATGGAAGTCACTTTTGGATGGCACCTGTGTAG			
N-gene-TBIP	TGCGGCCAATGTTTGTAAATCAGTTTCCAAGGAAATTTGGGGAC			
Gene N2-F3	ACCAGGAACTAATCAGACAAG	29136-29156 in GeneBank: MT007544.1	Zhang Y <i>et al.</i> [27]	1 <sup>a</sup> 2 <sup>b</sup> 3 <sup>c</sup>
Gene N2-B3	GACTTGATCTTTGAAATTTGGATCT	29299-29323 in GeneBank: MT007544.1		
Gene N2-LF	GGGGGCAAATTGTGCAATTTG	Gene N of SARS-CoV-2		
Gene N2-LB	CTTCGGGAACGTGGTTGACC			
Gene N2-FIP	TTCCGAAGAACGCTGAAGCG-GAACTGATTACAAAATTGGCC			
Gene N2-BIP	CGCATTGGCATGGAAGTCACTTTGATGGCACCTGTGTA			
Gene N2-TFIP	TTCCGAAGAACGCTGAAGCGTTTGAAGTCACTTTGATGGCACCTGTGTA			
Gene N2-TBIP	CGCATTGGCATGGAAGTCACTTTAATTTGATGGCACCTGTGTA			
ACTB-F3	AGTACCCCATCGAGCACG	287-304 in NM_001101.5	Zhang Y <i>et al.</i> [27]	1 <sup>a</sup> 2 <sup>b</sup> 4 <sup>d</sup> 5 <sup>e</sup>
ACTB-B3	AGCCTGGATAGCAACGTACA	479-498 in NM_001101.5		
ACTB-LF	TGTGGTGCCAGATTTTCTCCA	Human ACTB mRNA		
ACTB-LB	CGAGAAGATGACCCAGATCATGT			
ACTB-FIP	GAGCCACACGCAGCTCATTGTATCAACCACTGGGACGACA			
ACTB-BIP	CTGAACCCCAAGGCCAACCGGCTGGGGTGTGAAGGTC			
ACTB-TFIP	GAGCCACACGCAGCTCATTGTATTTTCAACCACTGGGACGACA			
ACTB-TBIP	CTGAACCCCAAGGCCAACCGTTTGGCTGGGGTGTGAAGGTC			

114 Summary of the above primer sets in optimization phases

115 <sup>a</sup>Phase 1: Primer screening with 30 copies of synthetic SARS-CoV-2 RNA (all primer sets)

116 <sup>b</sup>Phase 2: Defining LoDs with 30, 60, 120 and 240 copies of synthetic SARS-CoV-2 RNA or 0.01, 0.05, 0.25 and 1.25ng of human RNA (ORF1a, E1, N-gene N2,  
117 and ACTB)

118 <sup>c</sup>Phase 3: Maximizing sensitivity by primer multiplexing and supplementation GuHCl and/or Betaine with 15 copies of SARS-CoV-2 synthetic RNA (ORF1a  
119 and E1)

120 <sup>d</sup>Phase 4: Detecting SARS-CoV-2 with extracted RNA from clinical NP samples by multiplexing ORF1a and E1 and supplementing GuHCl and Betaine (ORF1a  
121 and E1)

122 <sup>e</sup>Phase 5: Detecting SARS-CoV-2 with raw clinical NP samples by multiplexing ORF1a and E1 and supplementing Betaine and Igepal CA-630  
123 (ORF1a and E1)

## 124 Control SARS-CoV-2 RNA



125 Synthetic SARS-CoV-2 viral RNA sequences were ordered from Twist Bioscience (Cat.  
126 No. 102019,  $1 \times 10^6$  RNA copies/ $\mu$ l), and they were non-overlapping fragments of the genome  
127 appropriate for each set of primers. The viral RNAs were diluted with DNase/RNase-free water  
128 accordingly based on the need of experiments.

## 129 **Clinical nasopharyngeal (NP) samples**

130 Canadian samples: 30 SARS-CoV-2 positive and 36 negative heated-inactivated clinical  
131 NP samples in Universal Transport Medium (UTM) were provided by the Microbiology  
132 Department of Mount Saini Hospital in Toronto Canada. These samples were collected from  
133 January to July 2020. The sample size was determined based on FDA recommendation regarding  
134 development of molecular diagnostic test for SARS-CoV-2 [23]. The samples were kept at  $-80^{\circ}\text{C}$   
135 in a Viral Tissue Culture (VTC) laboratory in the Lunenfeld-Tanenbaum Research Institute  
136 (LTRI), and all the experiments related to these samples were performed in the VTC lab. These  
137 samples were surplus diagnostic materials that were analyzed anonymously, and no specific  
138 approval from Research Ethics Board (REB) was required. The clinical information regarding  
139 these samples was not known.

140 Colombian samples: Two batches of clinical NP swab samples were chosen from the  
141 samples collected previously for the Uniandes COVIDA project, and were collected between  
142 February 16th and March 29th of 2021. Batch 1: 134 positive and 50 negative samples were re-  
143 evaluated by qRT-PCR with freshly extracted RNA to confirm SARS-CoV-2 status and sample  
144 integrity. With the exclusion of the degraded samples, 41 negative samples and 118 positive  
145 samples with Ct values for SARS-CoV-2 Orf1ab from 15 to 36.4 were selected to optimize direct  
146 RT-LAMP. Batch 2: 120 positive and 120 negative samples were randomly chosen, and re-

147 evaluated to confirm SARS-CoV-2 condition and sample quality. With the exclusion of the  
148 invalid, degraded samples, 88 positive and 120 negative samples were selected to test the direct  
149 RT-LAMP assay.

150 Ecuadorian samples: 21 positive and 21 negative NP swab samples were collected from  
151 February to August 2021 in Quito Ecuador. These samples were used to test the optimized RT-  
152 LAMP with extracted RNA and raw samples.

### 153 **RNA extraction from clinical NP samples**

154 Canadian samples: RNA extraction from clinical NP samples was carried out with  
155 miRNeasy Mini Kit (Qiagen, Cat. No. 217004) according to the kit instructions. For all the  
156 SARS-CoV-2 positive or negative NP samples, 50µl was aliquoted for RNA extraction, and the  
157 extracted RNA was eluted out with 50µl DNase/RNase free water.

158 Colombian samples: Batch 1: RNA extraction was performed with Quick-RNA viral kit  
159 (Zymo, Cat. No. R1035-E). 100µl of sample was applied for extraction, and RNA was eluted in  
160 50µl RNase free water. Batch 2: Extraction was performed using the Nextractor NX-48S  
161 (Genolution), an automated system for rapid DNA/RNA isolation, 200 µl of sample was applied  
162 for extraction. RNase free water was added to the eluted until it reached the 200 µL.

163 Ecuadorian samples: RNA extraction was performed with ExtractMe viral RNA kit  
164 (Blirt, Cat. No. EM39) following manufacturer's instructions. 100µl of sample was used for  
165 extraction, and RNA was eluted out with 30µl RNase free water.

### 166 **Generation of contrived positive NP samples**

167 To better evaluate the detection sensitivity of the maximized RT-LAMP with raw NP  
168 samples, 12 SARS-CoV-2 positive clinical NP samples from the Canadian cohort were diluted  
169 with 12 negative clinical NP samples to create 56 contrived positive NP samples with predicated  
170 Ct values between 21.0 and 31.0.

## 171 **Optimization of RT-LAMP**

172 Before setting up the RT-LAMP experiments, bench surface, racks and pipettes were  
173 cleaned with 10% bleach and 70% alcohol to avoid contamination. The main reagents for RT-  
174 LAMP were WarmStart colorimetric LAMP 2X Master Mix (NEB, Cat. No. M1800L) and 5mM  
175 STYO 9 Green Fluorescent Nucleic Acid Stain (Life technologies, Cat. No. S34854). Other  
176 reagents for the optimization were GuHCl (Sigma-Aldrich, Cat. No. G3272-25G), 5M betaine  
177 (Sigma-Aldrich, Cat. No. B0300-1VL) and Igepal CA-630 (Sigma-Aldrich, Cat. No. I8896). The  
178 volume for each RT-LAMP reaction was 10 $\mu$ l, including 5 $\mu$ l WarmStart colorimetric LAMP 2X  
179 Master Mix, 1 $\mu$ l 10X primer set stock and 1 $\mu$ l template. The remaining volume was filled with  
180 H<sub>2</sub>O or supplements. The RT-LAMP reactions were set up on ice, and were carried out with  
181 384-well plates (ThermoFisher, Cat. No. 4309849) at 65°C using CFX 384 Real-Time System  
182 (BIO-RAD) operated with Bio-Rad CFX manager 3.1. The plate reading was set for SYBR green  
183 reading, and read every 30 seconds, total 120 reads. At the end of the experiments, color images  
184 of the 384-well plates were scanned with a Canon photocopier because the commercial RT-  
185 LAMP kit is designed to produce a change in solution color from pink to yellow with the  
186 presence of amplification. In the experiments performed with FluoroPLUM (LSK Technologies  
187 Inc., Cat. No. SPF), 96-well plates (Luna Nanotech, Cat. No. MPPCRN-NH96W) were used.  
188 The optimized RT-LAMP recipes for various conditions were in Table 2. The optimized RT-

189 LAMP assays were evaluated in Colombian and Ecuadorian laboratories with CFX96<sup>TM</sup> Real-  
 190 Time System (BIO-RAD) using 96-well plates (BIO-RAD, Cat. No. HSP9601).

191 **Table 2. Optimized RT-LAMP conditions**

Templates	Primer concentrations	Supplements <sup>a</sup>	SYTO 9 <sup>a</sup>	Instruments
Extracted RNA for SARS-CoV-2	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	40mM GuHCl	1µM	CFX 384 Real-Time System
	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine		
Extracted RNA for ACTB	ACTB: F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	40mM GuHCl 0.5M betaine	1µM	CFX 384 Real-Time System
Raw NP samples for SARS-CoV-2	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine	1µM	CFX 384 Real-Time System
	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.25% Igepal CA-630		
Raw NP samples for ACTB	ACTB: F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	0.5M betaine 0.25% Igepal CA-630	1µM	CFX 384 Real-Time System
Raw NP samples for SARS-CoV-2	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine	10µM	FluoroPLUM
	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.25% Igepal CA-630		
Raw NP samples for ACTB	ACTB: F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	0.5M betaine 0.25% Igepal CA-630	10µM	FluoroPLUM

192 <sup>a</sup>Appropriate concentrations for experiments were prepared with DNase/RNase-free water

## 193 RT-qPCR

194 Canadian samples: Before performing experiments, bench surface, racks and pipettes  
 195 were cleaned with 10% bleach, 70% alcohol and DNAZap (Thermofisher, Cat. No. AM9890).  
 196 BGI Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 (Cat. No. MFG030018)  
 197 was applied according to the kit instructions with some modifications. RT-PCR reagents and  
 198 RNA samples were thawed and kept on ice. For each 10µl RT-PCR reaction, 6.17µl SARS-CoV-  
 199 2 Reaction Mix, 0.5µl SARS-CoV-2 Enzyme Mix, 2.33µl DNase/RNase-free water and 1µl  
 200 template was loaded to a well of 384-well plate (BIO-RAD, Cat. No. HSP3805). The RT-PCR  
 201 reaction was carried out with CFX 384 Real-Time System (Bio-Rad Laboratories) operated with

202 Bio-Rad CFX Manager 3.1, and the plate reading was set as defined by the kit instructions for all  
203 channel reading. A sample was defined as SARS-CoV-2 positive if the Ct for ORF1ab was <  
204 37.0. A sample was defined as ACTB positive if the Ct for ACTB was < 35.0.

205 Colombian samples: U-TOP Season RT-PCR kit was used to detect viral RNA and  
206 human RNase P gene following the kit instructions. A sample was defined as SARS-CoV-2  
207 positive if Ct value for Orf1ab and/or N gene was  $\leq 38$ . The cutoff for RNase P was  $Ct \leq 38$  as  
208 well.

209 Ecuadorian samples: The qRT-PCR was performed with an in-house assay with targets  
210 in the N and E genes based on the following protocols [29,30]. The SuperScript™ III Platinum™  
211 One-Step RT-qPCR Kit (Invitrogen, Cat. No. 12574026) was used to detect specific targets. The  
212 cutoff Ct value for the gene E was 30, and 35 for the gene N and human ACTB.

## 213 **Evaluation of RT-LAMP performance with receiver operating** 214 **characteristic (ROC) curve analysis**

215 For all the positive and negative clinical NP samples confirmed by BGI RT-PCR kit, RT-  
216 LAMP TTR or  $\text{slope}_{20-40}$  was plotted in functions of the true positive rate (Sensitivity) and the  
217 false positive rate (1-Specificity) for ROC curve analysis using MedCalc software [31]. The area  
218 under the ROC curve (AUC) and cut-off TTR or  $\text{slope}_{20-40}$  at which the true positive plus true  
219 negative rate is highest was calculated. More stringent cutoffs were used in some cases, as  
220 indicated in the text, to achieve 100% specificity [23].

## 221 **Results**

### 222 **Phase 1: Screening primers at a low template copy number**

223           The RT-LAMP reagent used in this study is WarmStart®Colorimetric LAMP 2X Master  
224 Mix (NEB, Cat. No. M1800L), and employed four core primers: FIP (forward inner primer), BIP  
225 (backward inner primer), F3 (forward primer), B3 (backward primer) to amplify the target  
226 region, and two loop primers, LF (loop forward) and LB (loop backward), to enhance reaction  
227 speed (Fig 1A). In LAMP reactions, non-specific amplification is common due to *cis* and *trans*  
228 priming among the six primers [32]. Robust performance of RT-LAMP requires thorough  
229 optimization of the six primers over a wide range of concentrations [33]. Including a “TTTT”  
230 linker between the F1c and F2 as well as B1c and B2 regions of FIP and BIP (Fig 1A) can  
231 improve sensitivity [25,34]. Thus, to optimize SARS-CoV-2 detection, we tested 14 primer sets  
232 (7 with and 7 without a TTTT insert), which included 12 targeting SARS-CoV-2 and 2 for  
233 human  $\beta$ -actin (ACTB, Fig 1B and Table 1). The pilot screen tested 16 different primer  
234 concentrations, representing four different primer ratios, with four replicates per test condition  
235 (Fig 1C). Accurate estimation of sensitivity and specificity requires more replicates, but we  
236 limited the pilot screen to quadruplicates in view of the large survey matrix (14 primers x 16  
237 conditions x 4 replicates = 896 reactions). This approach provided initial approximate  
238 sensitivity/specificity estimates to select primers and primer amounts for the next test phase.

239

240 **Fig 1. Screening primer performance at a low copy number of SARS-CoV-2 RNA.** (A) A  
241 schematic showing a DNA template amplified by LAMP and the primers targeted to the regions

242 in the template. (B) Location of the 7 target regions for the 14 primer sets in the SARS-CoV-2  
243 genome (NC\_045512.2, [35]). The indicated target region is that amplified by the outer F3 and  
244 B3 primers. (C) Matrix of test conditions. Each primer set was tested with the indicated primer  
245 molar ratio (black), and primer concentrations (blue). A total of 16 conditions were tested for  
246 each of the 14 primer sets, with 4 replicates per condition. Other reaction reagents are indicated  
247 in red. (D) Screening results for primer Gene E1. Top panel: For the indicated primer mixes (X-  
248 axis), red and blue bars indicate TTR using 30 copies of positive control SARS-CoV-2 RNA  
249 ( $TTR^{PC}$ ) or no template ( $TTR^{NTC}$ ), respectively. Red and blue circles indicate sensitivity and  
250 specificity, respectively. Bottom left graph shows an example of the fluorescent signal obtained  
251 with STYO 9 dye over the 60 minute reaction period for PC (red) or NTC (blue – undetected)  
252 using the indicated Gene E1 primer mix. Green line: threshold to designate TTR. Bottom right  
253 panel shows an example of the phenol red colour at 60 minutes. (E and F) Screening results of  
254 primer ORF1a (E) and human ACTB (F); format as in (D). (G) Summary of the best two primer  
255 concentrations for the top performing four primer sets with adequate performance based on  
256 sensitivity, specificity and TTR. NTC, no template control; PC, positive control (30 copies of  
257 SARS-CoV-2 RNA); Sensitivity, the percentage of PC replicates with amplifications;  
258 Specificity, the percentage of NTC replicates without amplifications; RFU, relative fluorescence  
259 units; TTR, time to results (minutes), the time point that the RFU curve crossing the fluorescent  
260 threshold; Error bars represent mean  $\pm$  standard deviations.

261

262 To develop a sensitive RT-LAMP assay, we used only 30 copies of synthetic SARS-  
263 CoV-2 RNA (Twist Bioscience) in these primer comparisons. To optimize RT-LAMP for  
264 ACTB, we used 5ng human RNA. RT-LAMP reactions were carried out at 65°C in a

265 thermocycler. 1  $\mu$ M SYTO 9 green fluorescent dye was used to track the time to result (TTR) in  
266 min., deemed as the point at which the RFU (relative fluorescence units) curve crosses the  
267 fluorescent threshold (green line, Fig 1D). TTR values were plotted together with sensitivity (%  
268 confirmed positives/ positives tested) and specificity (% confirmed negatives/negative controls  
269 tested). The commercial RT-LAMP kit also contains phenol red, which changes from pink to  
270 yellow with successful amplification, thus we also recorded color at the end of each experiment.  
271 Primer concentration and type affected the specificity of RT-LAMP reactions considerably (Figs  
272 1D-1F and S1 Fig), and from this survey the best two primer concentrations of the four top-  
273 performing viral primer sets and the best ACTB primer sets were prioritized for Phase 2 (Fig  
274 1G). The selected primer sets included Gene E1, N-gene, Gene N2, and ORF1a, which  
275 displayed excellent TTR (~10-14 min), sensitivity (all 100% except Gene N2) and specificity (all  
276 100%). The “TTTT” linker did not improve or impaired performance for 6/7 of the SARS-CoV-  
277 2 and the ACTB primers, and although it did improve detection with Gene N-A primers, these  
278 remained inferior to the four selected viral primers (S1A Fig). The two best concentrations for  
279 ACTB primers were much lower than those of the SARS-CoV-2 primers, and also exhibited a  
280 lower TTR than viral primers (Figs 1F and 1G).

## 281 **Phase 2: Selection of primers with optimal LoD and specificity**

282 In Phase 2, we increased replicates to 10 (from 4), and assessed 4 (rather than 1) viral  
283 template amounts (30, 60, 120, 240 copies). We also assessed four template amounts for ACTB  
284 primers (0.01, 0.05, 0.25 or 1.25 ng human RNA). In total, therefore, Phase 2 involved 400  
285 reactions (5 primer sets x 2 primer concentrations x 10 replicates x 4 template concentrations).  
286 The LoD is commonly defined as the concentration of analyte that can be detected in 95% of



287 replicates [36], but as we used 10 replicates in this phase, we defined LoD as the lowest copy  
288 number at which sensitivity was 100% after 30 min. Specificity was calculated using the no  
289 template control (NTC) reactions at both 45 and 60 min. time points, which was used together  
290 with the LoD to stratify primer sets (Fig 2A and S2 Fig). ORF1a, E1 and N2 primers at the  
291 0.2/3.2/0.4 uM F3B3/FIPBIP/LFLB ratio were the top performers, with LoDs of 120, 240 and  
292 240 copies, respectively and 100% specificity at 45 min (Fig 2A and S2D, S2A and S2C Figs).  
293 The alternate F3B3/FIPBIP/LFLB ratio for these primers also performed well, but the LoD  
294 and/or specificity was marginally weaker (Fig 2A and S2D, S2A and S2C Figs). The N-gene  
295 primer set LoDs were similar to the E1 and N2 primers, but specificity was slightly worse at 60  
296 min (Fig 2A and S2B Fig), thus we excluded it from Phase 3. The LoD for the ACTB primers  
297 was 100% at all four template concentrations. However, ACTB primer specificity was 100% vs.  
298 80% at both 45 and 60 min with the 0.05/0.04/0.1 uM FB3/FIPBIP/LFLB ratio (Fig 2B and S2E  
299 Fig), which was thus selected for Phase 3.

300

301 **Fig2. Evaluation of the optimized primer concentrations based on limit of detection and**  
302 **specificity.** (A) ORF1a, Gene E1, Gene N2 and N-gene primers were assessed at the indicated  
303 conditions. Each condition was evaluated with 10 replicates. (B) ACTB primers were evaluated  
304 under the indicated conditions. Sensitivity, the percentage of replicates with SARS-CoV-2 RNA  
305 or human RNA showing amplifications; Specificity, the percentage of no template controls  
306 without amplifications; TTR, time to results (minutes); LoD, limit of detection; Error bars  
307 represent mean  $\pm$  standard deviations.

308

### 309 **Phase 3: Maximizing sensitivity and specificity with primer** 310 **multiplexing and supplements**

311 Multiplexed LAMP assays can be used to simultaneously test for multiple pathogens by  
312 labeling primers for different pathogens with different fluorophores [37,38]. Here, we tested  
313 whether multiplexing the best primer sets from Phase 2 (ORF1a, E1 and N2) improves detection  
314 sensitivity of SARS-CoV-2. To reveal differences in sensitivity, we used only 15 copies of viral  
315 template, and ran 10 replicates each to compare E1, N2 or ORF1a primer sets alone, or each of  
316 the three possible pairings (Fig 3A and S3A Fig). To calculate sensitivity, only fluorescent  
317 signals that appeared within 30 mins were counted, whereas specificity of fluorescent NTC  
318 reactions were assessed for 60 min. Color reactions were also visually inspected at 60 min. At 15  
319 template copies, the N2 primer sets alone failed, while the E1 or ORF1a primer sets alone  
320 exhibited < 50% sensitivity, and only the latter provided 100% specificity (Fig 3A and S3A Fig).  
321 Notably, each of the three primer set pairings improved sensitivity, and the best success rate of  
322 70% success was achieved with the E1 + ORF1a combination, with a mean TTR of < 15 min,  
323 and 100% specificity (Fig 3A). At 60 min, 9/10 template reactions (90%) generated the  
324 anticipated color change with the E1 + ORF1a combination, while 10/10 NTC reactions  
325 remained red (S3B Fig). This dual target primer mix was then taken forward to test whether  
326 various additives might further improve performance.

327

328 **Fig 3. Effect of primer multiplexing and supplements.** (A) Evaluation of RT-LAMP  
329 performance with the indicated primer multiplexing. RT-LAMP reactions were carried out with  
330 15 copies of SARS-CoV-2 RNA at the optimized concentration for each primer set (see Fig 2A

331 in bold). (B) Evaluation of RT-LAMP performance with 40mM GuHCl and/or 0.5M betaine.  
332 Reactions were performed with multiplexed Gene E1 and ORF1a primers. (C) LoD assessment  
333 of the best RT-LAMP condition with the indicated copy numbers of SARS-CoV-2 RNA. (D)  
334 Fluorescent readouts and color changes of the reactions in (C) at 60 minutes. Each condition was  
335 evaluated with 10 replicates. NTC, no template control; TTR, time to results; RFU, relative  
336 fluorescent units; Error bars represent mean  $\pm$  standard deviations.

337

338 A recent study demonstrated that 40 mM of the denaturing agent guanidine hydrochloride  
339 (GuHCl) improves the sensitivity of detection of synthetic SARS-CoV-2 RNA, although patient  
340 samples were not tested [27]. A separate study reported that GuHCl did not improve results with  
341 patient samples [39]. Betaine, which improves PCR amplification of GC-rich DNA sequences  
342 [40], can also enhance RT-LAMP [41,42]. Thus, we tested whether GuHCl and/or betaine  
343 improves sensitivity with the E1 + ORF1a primer combo with 15 copies of viral template. In the  
344 unmodified reaction, sensitivity was, as before, 70%, while specificity at 60 min dropped in this  
345 experiment from 100% to 90% (*c.f.* Fig 3A vs. Fig 3B and S3C Fig), although this aberrant  
346 signal appeared beyond 50 min., well after the 30 min. cutoff used to define sensitivity (S3C  
347 Fig). Adding GuHCl alone, or more so Betaine alone, reduced sensitivity, but combining GuHCl  
348 + Betaine elevated sensitivity to 80%, and in all three of these conditions, specificity was 100%  
349 (Fig 3B, S3C and S3D Figs). With this optimized condition, we ran 10 replicates on 4 viral  
350 template amounts (7.5, 15, 20, 25 copies), which defined the LoD as 20 copies (2 copies/ $\mu$ l)  
351 (Figs 3C and 3D). One out of 10 NTC reactions generated an aberrant signal, but again at  
352 beyond 50 min. (Fig 3D). Thus, the combination of E1 and ORF1a primers together with GuHCl  
353 and Betaine provided the most sensitive detection of synthetic SARS-CoV-2 RNA.

## 354 **Phase 4: Optimized RT-LAMP is comparable to a clinical RT-PCR** 355 **test with extracted RNA**

356 To test the efficiency of the maximized RT-LAMP in detecting SARS-CoV-2 RNA from  
357 clinical patient samples, we tested 30 positive and 36 negative NP samples. RNA was extracted  
358 and RT-PCR performed with the BGI RT-PCR kit, which is used in the clinic to detect SARS-  
359 CoV-2 ORF1ab and human ACTB [43,44]. Ct values correlated well with clinical Ct values from  
360 other detection methods in the positive samples (Fig 4A), and no SARS-CoV-2 was detected in  
361 the 36 negative samples (not shown). We then ran RT-LAMP with the Phase-3-optimized  
362 conditions and plotted a receiver operator characteristic (ROC) curve of true positive rate (TRP)  
363 vs. false positive rate (FPR) ranked on TTRs to evaluate performance. Random assignment of  
364 test results generates a diagonal line from 0,0 to 100,100 with an area under the curve (AUC) of  
365 0.5, whereas a perfect test generates vertical line from 0,0 to 0,100 and an AUC of 1.0. RT-  
366 LAMP was comparable to the BGI RT-PCR assay, with an AUC of 0.971 (95% CI: 0.896 –  
367 0.997) ( $P < 0.0001$ ). The TTR at which the TPR + true negative rate (or 1-FPR) is highest was  
368 13.2 minutes, and at that cutoff the sensitivity and specificity of RT-LAMP was 90% (95% CI:  
369 73.5% - 97.9%) and 100% (95% CI: 90.3% - 100%), respectively. The latter satisfies a  
370 recommendation from the FDA that tests should exhibit 100% specificity [23]. Of the 3/30  
371 positive samples that were not detectable by RT-LAMP, all were borderline RT-PCR positives  
372 with Ct values of 36.0 – 37.0 (Fig 4C). RT-LAMP successfully detected human ACTB within 20  
373 min in all positive and negative samples (Figs 4D and 4E). Instead of using a thermocycler and a  
374 fluorescent readout, we re-ran RT-LAMP with the above 30 positive and 36 negative samples at  
375 65°C in a water bath for 25 minutes using the end-point colorimetric method, and observed

376 similar sensitivity and specificity (S4A Fig). Thus, with patient-extracted RNA, the optimized  
377 RT-LAMP reaction is essentially as sensitive as the gold standard RT-PCR assay used in the  
378 clinic, and can be performed using a method (heat source and detection) that is appropriate for  
379 low-resource settings.

380

381 **Fig 4. Comparison of RT-LAMP and BGI RT-PCR with extracted RNA from clinical NP**

382 **samples.** (A) Correlation of Ct values with BGI RT-PCR kit vs. other indicated RT-PCR

383 reagents in 30 SARS-CoV-2 positive clinical NP samples. (B) ROC curve evaluating RT-LAMP

384 performance with 30 positive and 36 negative Canadian clinical samples based on the results of

385 BGI RT-PCR kit. TPR: true positive rate; FPR: false positive rate. TTR  $\leq$  13.2' was defined as

386 the cut-off to distinguish positive from negative samples with 90% detection sensitivity and

387 100% specificity. (C) Distribution of RT-LAMP TTRs against BGI RT-PCR Ct values for 30

388 positive and 36 negative clinical NP samples. BGI RT-PCR and RT-LAMP positives were

389 defined by Ct  $<$  37.0 and TTR  $\leq$  13.2' respectively. (D) Distribution of human ACTB TTRs. (E)

390 Representative fluorescent readouts and phenol red colour with RT-LAMP reactions at 60

391 minutes in (C and D) with the clinical NP samples. (F) ROC curve evaluating RT-LAMP

392 performance with 21 positive and 21 negative NP samples from Ecuador. TTR  $\leq$  41' was defined

393 as the cut-off to distinguish positive from negative samples with 100% specificity and sensitivity.

394 (G) Distribution of RT-LAMP TTRs vs. RT-PCR Ct values for gene E with samples in (F). RT-

395 PCR and RT-LAMP positives were defined by Ct  $\leq$  30.0 for gene E and TTR  $\leq$  41' respectively.

396 (H) Distribution of human ACTB TTRs of samples in (F).

397

398 To further validate the LAMP assay, it was evaluated in the National Institute of Public  
399 Health Research (INSPI) in Ecuador, which employed different clinical protocols for RNA  
400 extraction and qRT-PCR to diagnose SARS-CoV-2 infection [29,30]. RT-LAMP was performed  
401 with 20 positive and 21 negative NP swab samples. ROC curve analysis indicated an AUC of 1.0  
402 (95% CI: 1.000 – 1.000) ( $P < 0.0001$ ), and defined the cutoff TTR as 41 minutes. With this  
403 cutoff TTR, the assay exhibited 100% sensitivity (95% CI: 83.9% - 100%) and 100% specificity  
404 (95% CI: 84.5% - 100%) (Figs 4F and 4G). Human ACTB was detected in all the samples within  
405 35 minutes (Fig 4H). Thus, the optimized RT-LAMP performed robustly on extracted patient  
406 RNA independent of location or RNA extraction and RT-PCR methods.

## 407 **Phase 5: SARS-CoV-2 detection in raw clinical NP samples without** 408 **RNA extraction**

409 The above tests require access to appropriate resources to purify RNA. Next, therefore,  
410 we utilized the clinical NP samples assessed in Phase 4 to determine whether RT-LAMP could  
411 be used as a PoC test for direct detection of SARS-CoV-2 without RNA extraction. We utilized  
412 the E1 + ORF1a dual primer set and compared amplification with no supplements or the addition  
413 of betaine and GuHCl alone or together. 1  $\mu$ l of raw patient sample in Universal Transport  
414 Medium (UTM) was assessed per 10  $\mu$ l reaction. RT-LAMP successfully detected human ACTB  
415 in all samples within 35 min across all the tested conditions, except for Betaine-alone  
416 supplementation where the TTRs of one positive and one negative sample were between 40-45  
417 minutes (S5A Fig). To optimize viral RNA detection, we initially assessed four conditions  
418 (labeled #2-4 in Fig 5A), which included no supplements, GuHCl alone, Betaine alone, or  
419 GuHCl + Betaine and employed ROC curves to identify valid tests. Using a cutoff of  $P < 0.001$ ,

420 recommended for comparing ROC curves [45], only Betaine ( $P < 0.0001$ ) generated an AUC  
421 (0.742) that was significantly different from a random test (Fig 5A). Comparing the ROC curves  
422 for each condition, the only significant difference was between Betaine alone and GuHCl alone  
423 (Fig 5A). These results differed from those obtained with purified RNA, where combining  
424 GuHCl and Betaine created a high-performance assay (Figs 3 and 4). These data underscore the  
425 importance of optimizing a PoC assay with raw clinical samples.

426

427 **Fig 5. Direct RT-LAMP on raw clinical NP samples without RNA extraction.** (A) ROC  
428 curves evaluating RT-LAMP performance on 30 positive and 36 negative clinical NP samples  
429 with the indicated supplements. 0.5M betaine + 0.25% Igepal CA-630 in green; 0.5M betaine in  
430 red; No supplements in pink; 40mM GuHCl + 0.5M betaine in light blue; 40mM GuHCl in  
431 black. 1 $\mu$ l of raw samples (without any sample processing) was applied to RT-LAMP reactions,  
432 and the reactions were carried out with multiplexing primers for Gene E1 and ORF1a.  
433 Significance values were calculated with MedCalc software for ROC curve analysis. TTR\*  
434 indicates the cutoff providing optimal sensitivity and specificity. (B) Distribution of the RT-  
435 LAMP TTRs vs. BGI RT-PCR Ct values with the indicated supplements. Dotted lines indicate  
436 cutoffs. (C) Representative fluorescent readouts of RT-LAMP with 0.5M betaine and 0.25%  
437 Igepal CA-630. (D) Sensitivity of RT-LAMP at the indicated Ct ranges. Left panel, Clinical NP  
438 samples. Right panel, Contrived positives generated by diluting clinical NP positives with  
439 negative NP samples.

440

441           Although ROC curve analyses confirmed that Betaine supplementation generates a useful  
442 test, sensitivity was only 43.3% (Fig 5A). As a fifth condition (labeled #1 in Fig 5A), we  
443 modified the Betaine-alone condition by adding 0.25% Igepal CA-630, a detergent that enhances  
444 RT-qPCR detection of influenza virus in MDCK cells without RNA extraction [46]. Specificity  
445 was 100% in both cases, but sensitivity and AUC increased to 53.3% and 0.771, respectively  
446 (Fig 5A). However, this was not significantly different from Betaine alone (sensitivity 43.3%,  
447 AUC 0.742), and was still well below the 90% sensitivity and AUC of 0.971 observed with  
448 purified RNA (*c.f.* Figs 4B and 5A). Comparing RT-PCR Ct values on purified RNA to RT-  
449 LAMP TTR values on raw samples illustrated that the latter performed best on high titer (low Ct)  
450 samples (Figs 5B and 5C). Plotting the Ct values of false negatives and true positives with  
451 Betaine + Igepal RT-LAMP clarified this bias; 100% (15/15) of samples with  $Ct \leq 26.6$  were  
452 detected, 25% (1/4) sample Ct from 27.1 - 30 were detected, and no samples (0/11) with  $Ct > 30$   
453 were detected (Figs 5C and 5D). In all samples, human ACTB was detected within 30 minutes  
454 (S5A Fig).

455           To better define sensitivity around the approximate cutoff, we diluted high titer positives  
456 with negative patient samples to generate a series of contrived positives with predicted Ct values  
457 in the desired range. Direct RT-LAMP detected ACTB in all cases (S5B Fig). Viral RT-LAMP  
458 indicated a sensitivity of 100% (95% CI: 67.6% – 100%), 80% (95% CI: 58.4% - 91.9%) and  
459 31.8% (95% CI: 16.4% - 52.7%) for samples with  $Ct \leq 25$ ,  $25 - 27.2$ , and  $27.2 - 29.2$ ,  
460 respectively, and all samples with a  $Ct \geq 30.0$  were false negatives (Fig 5D). In these Canadian  
461 samples, Ct values of 25, 27 and 30 corresponded to  $7.9 \times 10^6$ ,  $2.5 \times 10^6$  and  $3.2 \times 10^5$  copies of  
462 SARS-CoV-2 per mL of raw NP samples respectively. Thus, the optimized RT-LAMP assay  
463 used directly on 1  $\mu$ l of NP sample may be a useful screening tool to identify infectious



464 individuals bearing high viral loads [10–12], but should not be used to definitively rule out  
465 infection.

466 To test robustness, the assay was evaluated in the diagnostics laboratory, Universidad de  
467 Los Andes (Uniandes), Colombia, with 118 positive and 41 negative clinical NP samples. To  
468 account for degradation during storage, Ct values were re-assessed with the U-TOP Season kit  
469 (one-step RT-PCR). To establish a TTR cutoff for use in this setting we assessed 41 negatives  
470 and 118 positives, most of which had Ct values < 30. ROC curve analysis generated an AUC of  
471 0.916 ( $P < 0.0001$ ), and defined the cutoff TTR as 25 minutes with 100 % (95% CI: 91.4% -  
472 100%) specificity, recommended by the FDA [23] (Fig 6A). With this cutoff TTR, sensitivity on  
473 these selected samples was 49.2% (95% CI: 40.3% - 58.1%) (Fig 6A). As with the Canadian  
474 samples, plotting TTR vs. Ct showed more efficient detection in high titer (lower Ct) samples  
475 (Fig 6B). Sensitivity was 91.4% (95% CI: 80.1% – 96.6%) at Ct < 23, but dropped to 39.1%  
476 (95% CI: 22.2% – 59.2%), 23.8% (95% CI: 10.6% – 45.1%), and 6.7% (95% CI: 0.3% – 29.8%)  
477 for samples with Ct 23 – 25, 25 – 27, and 27 – 30, respectively, and all samples with a Ct > 30  
478 were false negatives (Fig 6B). The assay detected ACTB in all 159 samples within 40 minutes  
479 except 3 positive samples (Fig 6C).

480

481 **Fig 6. Direct RT-LAMP on raw clinical NP samples of Colombia and Ecuador.** (A) ROC  
482 curve evaluating the optimized direct RT-LAMP performance on 118 positive and 41 negative  
483 clinical NP samples from Colombia. (B) Distribution of the RT-LAMP TTRs vs. U-TOP Season  
484 RT-PCR Ct values for Orflab, and the sensitivity of RT-LAMP at the indicated Ct intervals with  
485 samples in (A). (C) Distribution of ACTB TTRs of samples in (A). (D) Plot of TTRs vs. Ct

486 values in a simulation RT-LAMP test with randomly chosen Colombian samples, and the  
487 sensitivity at the indicated Ct intervals with these samples. (E) ROC curve analysis validating the  
488 simulation RT-LAMP test in (D). (F) Distribution of ACTB TTRs of samples in (D). (G) ROC  
489 curve analysis of the direct RT-LAMP with 21 positive and 21 negative NP samples of Ecuador.  
490 (H) Distribution of the direct RT-LAMP TTRs vs. RT-PCR Ct values for E gene, and the  
491 sensitivity at the indicated Ct values for samples in (G). (I) Distributions of ACTB TTRs of  
492 samples in (G). Dotted lines in distribution graphs indicate cutoffs.

493

494 Using the above TTR cutoff, a simulation test of direct RT-LAMP was then performed  
495 with 208 randomly chosen samples (88 positive, 120 negative). We observed 100% specificity  
496 (95% CI: 96.9% - 100%) at the preselected TTR cutoff, while sensitivity was again dependent on  
497 Ct values, varying from 90.0% (95% CI: 69.9% – 98.2%), 83.3% (95% CI: 43.6% – 99.1%),  
498 85.7% (95% CI: 48.7% – 99.3%), for samples with Ct  $\leq$  23, 23 – 25, and 25 – 27 respectively,  
499 but dropping to 6.7% (95% CI: 0.3% – 29.8%) when Ct was 27-30, and all samples with a Ct >  
500 30 were false negatives (Fig 6D). Overall, sensitivity in this setting with these randomly selected  
501 samples was only 36.4%, below the 53.3% observed in the Canadian lab (Table 3). The  
502 performance of the assay in this simulation test was validated by ROC curve analysis with an  
503 AUC 0.854 ( $P < 0.0001$ ) (Fig 6E). Human ACTB was detected in all 208 samples within 40  
504 minutes except for 5 positive and 8 negative samples (Fig 6F).

505 Finally, direct RT-LAMP was also tested in INSPI laboratory in Ecuador with 21 positive  
506 (all reconfirmed Ct values  $\leq$  30 for Gene E) and 21 negative NP samples. ROC curve analysis  
507 confirmed performance with an AUC 0.882 (95% CI: 0.770 – 0.994) ( $P < 0.0001$ ), sensitivity

508 71.4% (95% CI: 50.0% - 86.2%) and specificity 100% (95% CI: 84.5% - 100%) at the TTR  
509 cutoff defined in this setting of 45 minutes (Fig 6G). As with the Canadian and Colombian data  
510 sets, sensitivity was higher in samples with low Ct values (Fig 6H). ACTB was detected within  
511 45 minutes in most of the samples (Fig 6I). Together, these multi-centre studies suggest that this  
512 direct RT-LAMP assay has utility as a PoC test to screen contagious individuals with high viral  
513 loads to limit transmission. These data also highlight the real-world fluctuations in sensitivity  
514 associated with distinct detection platforms in different locations.

## 515 **Phase 6: Direct RT-LAMP with a PoC device: FluoroPLUM**

516 The above direct RT-LAMP protocol removes the need for RNA extraction, but requires  
517 a thermocycler. Thus, to further aid PoC testing, we tested a low cost combined incubator and  
518 plate reader, FluoroPLUM, developed by LSK Technologies Inc. This device incubates the  
519 reaction chamber up to 65°C and utilizes royal blue LEDs (Luxeon, 440 nm ~ 455 nm), a long  
520 pass filter with 515 nm cutoff, and a camera to track change in green channel fluorescence  
521 intensity of DNA-bound SYTO 9. Once a 96-well sample plate is loaded on the tray, the device  
522 automatically detects wells of interest from captured images and monitors the reaction for 50  
523 minutes. Based on a digital map of the multiwell plate used for the experiments, PLUM software  
524 automatically displays graphed results on the screen at the end of the assay (Figs 7A and 7B). It  
525 is portable and can be operated on any global power supply using the correct plug adaptor, or a  
526 portable 12V 10A battery (8-9 h), making it ideal for PoC testing. To interpret the results in  
527 FluoroPLUM, we used linear regression to measure “slope<sub>20-40</sub>” (Fig 7C), as it provided easier  
528 differentiation among positive and negative samples compared to TTR used in thermocyclers.  
529 Slope<sub>20-40</sub> is calculated using all the data points between 20 – 40 mins, during which

530 amplification typically occurs in direct RT-LAMP (Figs 5A-5C and 7A). An increase in the  
531 concentration of SYTO 9 (10 $\mu$ M) performed better in FluoroPLUM reactions than lower  
532 concentrations (S6 Fig and Table 2) and, accordingly, was used in all subsequent assays. From  
533 the same group of raw Canadian clinical NP samples as before, we determined slope<sub>20-40</sub> for 30  
534 positive and 29 negative samples and ran ROC analysis. FluoroPLUM generated an AUC of 0.79  
535 ( $P < 0.0001$ ), comparable to data obtained with a thermocycler (*c.f.* Figs 5A and 7D). The  
536 slope<sub>20-40</sub> at which sensitivity + specificity is highest was 0.0004, and at that cutoff the sensitivity  
537 and specificity of RT-LAMP was 70% and 86%, respectively. The latter does not meet FDA  
538 guidelines of 100% specificity regarding SARS-CoV-2 molecular test development [23], so we  
539 used slope<sub>20-40</sub> > 0.0048 to define positives, as no false positives were detected above this cutoff.  
540 At this cutoff, sensitivity was 36.7% (95% CI: 21.9% to 54.5%), and specificity was 100% (95%  
541 CI: 88.3% to 100%). Sensitivity was 100% (95% CI: 67.6% - 100%) or 76.9% (95% CI: 49.7% -  
542 91.8%) for samples with Ct < 22.5 or Ct < 25 respectively, and fell to only 6.3% at Ct > 25 (Fig  
543 7E). In these raw samples, Ct at 22.5 and 25 reflects viral titer at 5.0 X 10<sup>7</sup> and 7.9 X 10<sup>6</sup>  
544 copies/mL respectively. These results were consistent with reaction color changes visualized at  
545 the end of the experiment (Figs 7G and 7H). The assay efficiently detected human ACTB with  
546 98.3% sensitivity (58/59) (Figs 7F and 7H). Thus, the portable FluoroPLUM instrument, which  
547 can be deployed in PoC settings, performs similarly to the thermocyclers used in a diagnostic  
548 lab.

549

550 **Fig 7. Direct RT-LAMP with FluoroPLUM.** (A) FluoroPLUM readout of RT-LAMP  
551 assessment of the boxed wells in (B). Each solid line represents one reaction, monitored for 45  
552 minutes, and quantified as 'PLUM reading units'. N1A5 (red) and N1V5 (green) are examples of

553 positive and negative samples, respectively. The red dash line is the average reading of all the  
554 wells in the plate (B) for the first 3 minutes. (B) Image of RT-LAMP reactions at the end of the  
555 experiment. (C) Slope<sub>20-40</sub> for the two reactions indicated in (A) and (B). (D) ROC curve  
556 evaluating FluoroPLUM performance using slope<sub>20-40</sub> values. (E) Distribution of slope<sub>20-40</sub> values  
557 vs. BGI RT-PCR Ct values. Dotted lines indicate cutoffs (RT-LAMP: slope<sub>20-40</sub> > 0.0048 =  
558 positive, RT-PCR: Ct < 37 = positive). (F) Distribution of slope<sub>20-40</sub> for human ACTB in clinical  
559 NP samples. (G) Images of color changes for the 30 positive (red) and 29 negative (blue) clinical  
560 NP samples. Asterisks: three samples with no amplification of ACTB, two of which showed  
561 amplification in a repeat run (bottom image). (H) Sensitivity with end-point data in (G).

562

## 563 Discussion

564 Through stepwise optimization of a commercially available RT-LAMP reagent, we  
565 developed a SARS-CoV-2 RT-LAMP assay with the potential to be deployed as a PoC test for  
566 infectious cases. First, we systemically screened the performance of 7 primer sets (6 for SARS-  
567 CoV-2 and 1 for human ACTB), as well as different “TTTT” linker formats, over a wide range  
568 of concentrations using a low copy number synthetic SARS-CoV-2 target RNA. Based on  
569 sensitivity, specificity and TTR, Gene E1, Gene N2 and ORF1a primer sets were chosen with an  
570 ideal concentration for each primer. The ideal concentration for an ACTB primer set was also  
571 finalized. We found tremendous variability in performance and ideal concentrations across  
572 different primer sets, underscoring the value of the optimization matrix [33]. Multiplexing Gene  
573 E1, N2 and/or ORF1a primer sets as well as supplementing reactions with GuHCl and betaine  
574 improved sensitivity. The optimized RT-LAMP (multiplexed primers for Gene E1 and ORF1a

575 plus supplementation with 40mM GuHCl and 0.5M betaine) decreased the LoD from 240 copies  
576 with the original reagents to 20 copies of SARS-CoV-2 viral RNA per reaction. This  
577 improvement has diagnostic significance because each 10-fold increase in the LoD of a COVID-  
578 19 viral diagnostic test is expected to increase the false negative rate by 13% [47]. Mapping the  
579 optimal primer sets onto sequences of the dominant variants delta and omicron  
580 (<https://covariants.org/variants>) revealed no mismatches. Furthermore, the primer sets target  
581 different regions of viral genome, fulfilling an FDA recommendation that molecular tests detect  
582 more than one viral genome region [48].

583         With extracted RNA from clinical NP swab samples, we found the optimized RT-LAMP  
584 test was comparable to the BGI RT-qPCR kit, a diagnostic RT-PCR test with top detection  
585 sensitivity approved by the FDA [44,49]. ROC curve analysis showed that the AUC was 0.971  
586 ( $P < 0.0001$ ) with 90% sensitivity and 100% specificity. The BGI RT-qPCR protocol defines  
587 samples with  $Ct < 37$  for ORF1ab as SARS-CoV-2 positive. RT-LAMP successfully detected  
588 SARS-CoV-2 RNA in all positives except three with  $36 < Ct < 37$ , and detected human ACTB in  
589 all samples. Notably, the RT-LAMP test takes less than 20 minutes compared with 2 hours for  
590 RT-qPCR, and can be performed with a 65°C water bath. For low-resource settings, this reduces  
591 the capital investment for RT-qPCR infrastructure (~\$25,000), has the potential to bring high  
592 fidelity molecular diagnostics to distributed community testing, and reduces the per test cost  
593 from ~\$25 USD (RT-qPCR) to ~\$2.40 (RT-LAMP).

594         The same assay tested in Ecuador presented an AUC 1.0 with ROC curve analysis, 100%  
595 sensitivity and specificity, and detected human ACTB in all the samples. The assay, however,  
596 took about 40 minutes, which may reflect differences in reagent sources, sample handling, as  
597 well as instrument models. Thus it is important to optimize the cutoff TTR based on different

598 testing conditions. Nonetheless, the strong performance with extracted RNA samples in different  
599 countries suggests that RT-LAMP could be deployed when RT-qPCR is limited because of a  
600 lack of reagents and/or thermocyclers. Indeed, the WHO considers diagnostic tests with  
601 sensitivity  $\geq 80\%$  and specificity  $\geq 97\%$  as suitable replacements for laboratory-based RT-PCR if  
602 the latter cannot be delivered in a timely manner [50].

603         Although RT-PCR with purified RNA is the gold standard to confirm SARS-CoV-2  
604 infection, a major limitation is its long turnaround time, especially outside of larger urban  
605 centers, compromising test efficacy in terms of timely self-isolation and contact tracing. Rapid  
606 and economical PoC tests for SARS-CoV-2, together with masking and social distancing, are  
607 necessary to stop community transmission of the disease [51,52]. With this in mind and  
608 recognizing that minimum sample manipulation is essential for PoC tests [15], we next  
609 optimized RT-LAMP for raw Canadian NP swab samples without RNA extraction. The best  
610 condition used multiplexed Gene E1 and ORF1a primers and supplementation with 0.5M betaine  
611 and 0.25% Igepal CA-630. In  $< 32$  mins, the optimized RT-LAMP detected samples with  $Ct \leq$   
612 25 (viral load  $\geq 7.9 \times 10^6$  copies/mL) with 100% sensitivity, samples with  $25 < Ct \leq 27.2$  (viral  
613 load:  $2.6 \times 10^6 - 7.9 \times 10^6$  copies/mL) with 80% sensitivity and samples with  $27.2 < Ct \leq 29.2$   
614 (viral load:  $5.0 \times 10^5 - 2.0 \times 10^6$  copies/mL) with 31.8%. However, this direct test failed to  
615 detect SARS-CoV-2 in samples with  $Ct \geq 30$  (viral load  $\leq 3.2 \times 10^5$  copies/mL). For all the  
616 samples, the RT-LAMP detected human ACTB in less than 30 minutes. Detection of high titer  
617 samples was also demonstrated in labs in Colombia and Ecuador. In the former, an initial survey  
618 of 41 negative and 118 positive selected samples defined a cutoff TTR of 25 minutes, then a  
619 simulation detection test with 88 positive and 120 negative randomly chosen samples displayed  
620 100% specificity, and 90% sensitivity with high titer ( $Ct \leq 23$ ) samples. Overall, sensitivity in

621 the Bogota study was 33.4%, below the 55% seen in the Toronto lab. Human ACTB was  
 622 detected in more than 95% of the samples within 40 minutes. A smaller test in Ecuador with 21  
 623 positive (Ct < 30) and 21 negative samples indicated a cutoff TTR of 45 minutes, longer than  
 624 those of the Canadian and Colombian labs. These results underscore the importance of  
 625 optimizing RT-LAMP in different locations. Variability may arise from changes in reagents, the  
 626 logistics of sourcing reagents (e.g. international shipping, time in customs), equipment and  
 627 personnel, and/or heat-inactivation of clinical samples (Table 3). However, taken together, RT-  
 628 LAMP brings the potential for deploying molecular testing broadly and, even with a detection  
 629 threshold limit of Ct 27, could provide significant gains for public health efforts to contain  
 630 infection.

631

632 **Table 3. Comparisons with other RT-LAMP PoC SARS-CoV-2 tests**

Studies	Samples	Cts	Specificity	Overall sensitivity	Ct-specific sensitivity	Human gene	Sample pretreatment
This study Toronto, Canada	NP samples 30 positive 36 negative	19.0 – 36.9 Cutoff ≤ 37	100%	53.3%	100%, Ct ≤ 26.6 0%, Ct > 30	ACTB	56°C, 30 min*
This study Bogota, Colombia Optimization test	NP samples 118 positive 41 negative	15.9 – 36.0 Cutoff ≤ 38	100%	49.2%	91.4%, Ct < 23.0 0%, Ct > 30	ACTB	None
This study Bogota, Colombia Simulation test	NP samples 88 positive 120 negative	15.6 – 37.2 Cutoff ≤ 38	100%	36.4%	90%, Ct ≤ 23.0 0%, Ct > 30	ACTB	None
This study Quito, Ecuador	NP samples 21 positive 21 negative	16.3 – 28.9 Cutoff ≤ 30	100%	71.4%	91.7%, Ct < 20	ACTB	None
This study Toronto, Canada	NP samples 30 positive	19.0 – 36.9 Cutoff ≤ 37	100%	36.7%	100%, Ct < 22.5 76.9%, Ct < 25	ACTB	56°C, 30 min*



FluoroPLUM	29 negative				0%, Ct > 30		
Song et al. [18]	NP samples 19 positive 21 negative	20 – 36	100%	84%	100%, Ct < 32	None	56°C, 1 hour
Schermer et al. [19]	NP samples 74 positive 28 negative	14.3 – 38.2	89.3%	73%	97.3%, Ct < 30	None	98°C, 15 min
Amaral et al. [20]	Saliva samples 39 positive 15 negative	18 - 28	100%	85%	100%, Ct < 22.2	None	95°C, 30 min
Dao Thi et al. [21]	NP samples 128 positive 215 negative	0 - 40	99.5%	46.9%	90.5%, Ct < 25 17.9%, Ct: 30 - 35	None	95°C, 5 min
Papadakis et al. [22]	NP samples 96 positive 67 negative	8 - 34	100%	83.3%	100%, Ct ≤ 25 53.1%, Ct: 30 - 34	None	Pretreated with neutralizing buffer

633 \* , positive samples had been treated for viral inactivation before, not for the purpose of assay optimization

634

635 We compared our direct detection results to those of five other RT-LAMP studies (Table  
636 3). Dao Thi et al [21], based in Heidelberg Germany, used N-A gene primers in RT-LAMP, and  
637 observed sensitivity of ~47% at 99.5% specificity, which is in a similar range to each of our  
638 three cohorts (Table 3). Similar to our work, Schermer et al, based in Cologne Germany,  
639 developed a multiplex reaction that included guanidine [19]. They reported a sensitivity of 73%  
640 with randomly selected samples, above our best result of 53.3%, but specificity was only 89% in  
641 contrast to 100% in our study (Table 3). It would be interesting to run comparisons on the same  
642 samples with primer sets used in both studies. Song et al, using samples from Pennsylvania  
643 USA, used a two-step tube reaction (“Penn-RAMP”) in which recombinase polymerase

644 amplification (RT-RPA) was performed first in the lid, then after spin-down, RT-LAMP in the  
645 tube [18]. They reported 84% sensitivity at 100% specificity, and detected all samples with Ct <  
646 32. Thus, adding the RT-RPA step greatly enhances sensitivity. A drawback is that this strategy  
647 requires additional reagents and a centrifuge, which can pose a challenge for operation in low-  
648 resource settings. For example, as we experienced, there are no direct suppliers of RPA or  
649 LAMP reagents in Colombia or Ecuador, and orders can take 2-6 months to arrive. Moreover, we  
650 found the performance of some products was lower than what was experienced in Canada, likely  
651 due to disruption of the cold chain during transport or customs clearance. Nation-specific  
652 bureaucratic requirements can further delay reagent delivery; for example, the National Institute  
653 for Food and Drug Surveillance (INVIMA) in Colombia must approve all reagents, which can  
654 affect preservation of reagents requiring cold chain. All of these challenges have been  
655 exasperated in the pandemic with, for example, customs personnel working from home and  
656 slower administrative approval processes.

657       It is worth noting that Song *et al* also tested Penn-RAMP with virion RNA in a PoC  
658 heating block [18], but whether this approach works with raw samples to the extent seen in the  
659 dual-step tube format was not reported. Nevertheless, their data highlight the potential of using  
660 RPA to improve RT-LAMP. A study by Papadakis *et al* from Heraklion Greece developed a  
661 portable biomedical device for performing real-time quantitative colorimetric LAMP. They  
662 performed RT-LAMP with Bst DNA/RNA polymerase from SBS Genetech, and tested 67  
663 negative and 96 positive crude NP samples [22]. They reported 100% sensitivity at Ct ≤ 25 and  
664 53.1% sensitivity at Ct: 30 – 34 with 100% specificity. Compared with our results, their reported  
665 higher sensitivity at high Ct values is likely due to the polymerase used, which is extremely  
666 thermostable and also provides sensitive reverse transcriptase activity. In their study, samples

667 were pretreated with neutralization buffer. Finally, Amaral *et al* [20], based in Lisbon Portugal,  
668 assessed saliva rather than NP samples, which has the advantage of easier collection. They  
669 observed 85% sensitivity at 100% specificity, but the highest RT-PCR Ct value of their samples  
670 was only 28; indeed 100% sensitivity was only observed at Ct < 22.2 (Table 3). Overall, RT-  
671 LAMP alone seems best suited to detect high titer samples.

672 In the final phase of our diagnostic development program, we prototyped deployment of  
673 the assay with a portable “lab-in-a-box” that provided combined incubation, optical monitoring  
674 and graphing. Direct RT-LAMP with the FluorPLUM device displayed high sensitivity with high  
675 viral loads (76.9% for Ct < 25 and 100% for Ct < 22.5), which dropped dramatically with low  
676 viral loads (Ct > 25). Thus, most samples with viral load beyond  $7.9 \times 10^6$  copies/mL could be  
677 detected. These data were comparable to results obtained with thermocyclers, justifying future  
678 work to assess this strategy in the field. Work is on-going to provide a more robust platform for  
679 field testing to broaden accessibility of FluoroPLUM as a PoC device.

680 Through the lens of maintaining public health, the priority is not necessarily to determine  
681 whether a person has any evidence of SARS-CoV-2, but to quickly and accurately identify  
682 individuals who are infectious [14]. Various studies have shown that COVID-19 patient sample  
683 infectivity correlates with Ct values, and the infectious period corresponds to the period during  
684 which viral load is likely to be highest [10–12,53,54]. Furthermore, a recent study directly  
685 demonstrated that viral load of COVID-19 patients was a leading driver of SARS-CoV-2  
686 transmission [55]. In that study, 282 COVID-19 cases were tracked and only 32% led to  
687 transmission [55]. Among the 753 total contacts from these cases, the secondary attack rate  
688 overall was 17%. Critically, at the lower viral load ( $10^6$  copies per mL) the secondary attack rate  
689 was 12% compared to 24% when the case had a viral load of  $10^{10}$  copies per mL or higher [55].

690 In comparison with our RT-LAMP assay, the detection sensitivity for samples with Ct < 25  
691 (viral load > 7.9 X 10<sup>6</sup> copies per mL) was 76.9%, and 100% for samples with Ct ≤ 22.5 (viral  
692 load ≥ 5 X 10<sup>7</sup> copies per mL), suggesting most individuals with high risk for transmission  
693 would be identified. The turnaround time for laboratory-based RT-PCR testing is generally 24 to  
694 48 hours, and longer in remote areas due to the transport of samples, while the RT-LAMP assay  
695 would generate results on-site in less than one hour. Thus, our assay could potentially be  
696 deployed as a PoC test at distributed sample collection centers to identify individuals with high  
697 risk for transmission to mitigate virus spreading.

698 A limitation of our study is that we tested NP swab samples processed in research  
699 laboratories, not in the field. Nevertheless, the lab studies in Colombia and Ecuador indicate  
700 feasibility and set the stage for PoC tests. A limitation of all LAMP protocols is that both the  
701 supply and cold chains remain a major hurdle for low/mid income nations. Many countries lack  
702 the domestic capacity for diagnostic manufacturing and must import health care tools, which, in  
703 addition to possible delays and cost, can complicate the response to public health crises. Cell-  
704 free protein expression systems, produced from *E. coli*, offer an exciting solution, and indeed  
705 have been applied recently in Chile for detection of a plant pathogen [56]. This trend toward  
706 locally produced reagents promises to transform diagnostics and reduce costs by orders of  
707 magnitude. As a part of the ongoing collaboration among the laboratories included in this study,  
708 a research project to locally produce easy-to-implement low-cost kits for the molecular diagnosis  
709 of febrile diseases (Sars-Cov-2 and arbovirus), was recently funded by the Ministry of Sciences  
710 (Minciencias) in Colombia.

711 In summary, we developed a rapid RT-LAMP assay for SARS-CoV-2 detection which  
712 was essentially as accurate as the BGI RT-PCR kit with extracted RNA, suggesting that it can

713 substitute for laboratory RT-PCR testing. With raw NP samples, the direct RT-LAMP assay  
714 detected samples with high viral loads, positioning the assay well for future deployment as a PoC  
715 test to control virus spread.

716

## 717 **References**

- 718 1. Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19.  
719 JAMA. 2020;324: 2153–2154. doi:10.1001/jama.2020.21694
- 720 2. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2  
721 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19: 409–424.  
722 doi:10.1038/s41579-021-00573-0
- 723 3. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from  
724 [www.who.int/news/item/26-11-2021-classification-of-omicron](http://www.who.int/news/item/26-11-2021-classification-of-omicron).
- 725 4. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for  
726 Containment. N Engl J Med. 2020;383: e120. doi:10.1056/NEJMp2025631
- 727 5. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and  
728 transmissibility of COVID-19. Nat Med. 2020;26: 672–675. doi:10.1038/s41591-020-0869-5
- 729 6. Townsend JP, Wells CR. The Prognostic Value of an RT-PCR Test for Severe Acute Respiratory  
730 Syndrome Coronavirus 2 (SARS-CoV-2) Is Contingent on Timing across Disease Time Course in  
731 addition to Assay Sensitivity. J Mol Diagn. 2022;24: 101–103. doi:10.1016/j.jmoldx.2021.10.002
- 732 7. Tian D, Lin Z, Kriner EM, Esneault DJ, Tran J, DeVoto JC, et al. Ct Values Do Not Predict Severe  
733 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students. J Mol  
734 Diagn JMD. 2021;23: 1078–1084. doi:10.1016/j.jmoldx.2021.05.012
- 735 8. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to  
736 frequency and turnaround time for COVID-19 surveillance. MedRxiv Prepr Serv Health Sci. 2020.  
737 doi:10.1101/2020.06.22.20136309
- 738 9. Service RF. A call for diagnostic tests to report viral load. Science. 2020;370: 22.  
739 doi:10.1126/science.370.6512.22
- 740 10. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as  
741 determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from  
742 infectious disease wards. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020;39:  
743 1059–1061. doi:10.1007/s10096-020-03913-9

- 744 11. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious SARS-CoV-2  
745 from diagnostic samples. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020. doi:10.1093/cid/ciaa638
- 746 12. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, et al. Cell-based culture of SARS-  
747 CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. *Clin Infect Dis Off*  
748 *Publ Infect Dis Soc Am*. 2020. doi:10.1093/cid/ciaa1579
- 749 13. Chin ET, Lo NC, Huynh BQ, Murrill M, Basu S. Frequency of routine testing for SARS-CoV-2 to  
750 reduce transmission among workers. *MedRxiv Prepr Serv Health Sci*. 2020.  
751 doi:10.1101/2020.04.30.20087015
- 752 14. Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19.  
753 *JAMA*. 2020. doi:10.1001/jama.2020.21694
- 754 15. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen  
755 and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Infectious Diseases*  
756 *Group, editor. Cochrane Database Syst Rev*. 2021;2021. doi:10.1002/14651858.CD013705.pub2
- 757 16. Augustine R, Hasan A, Das S, Ahmed R, Mori Y, Notomi T, et al. Loop-Mediated Isothermal  
758 Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for  
759 Coronaviruses in the Context of COVID-19 Pandemic. *Biology*. 2020;9. doi:10.3390/biology9080182
- 760 17. MacKay MJ, Hooker AC, Afshinnkoo E, Salit M, Kelly J, Feldstein JV, et al. The COVID-19 XPRIZE  
761 and the need for scalable, fast, and widespread testing. *Nat Biotechnol*. 2020;38: 1021–1024.  
762 doi:10.1038/s41587-020-0655-4
- 763 18. Song J, El-Tholoth M, Li Y, Graham-Wooten J, Liang Y, Li J, et al. Single- and Two-Stage, Closed-  
764 Tube, Point-of-Care, Molecular Detection of SARS-CoV-2. *Anal Chem*. 2021;93: 13063–13071.  
765 doi:10.1021/acs.analchem.1c03016
- 766 19. Schermer B, Fabretti F, Damagnez M, Di Cristanziano V, Heger E, Arjune S, et al. Rapid SARS-CoV-2  
767 testing in primary material based on a novel multiplex RT-LAMP assay. *PLoS One*. 2020;15:  
768 e0238612. doi:10.1371/journal.pone.0238612
- 769 20. Amaral C, Antunes W, Moe E, Duarte AG, Lima LMP, Santos C, et al. A molecular test based on RT-  
770 LAMP for rapid, sensitive and inexpensive colorimetric detection of SARS-CoV-2 in clinical samples.  
771 *Sci Rep*. 2021;11: 16430. doi:10.1038/s41598-021-95799-6
- 772 21. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A colorimetric RT-LAMP  
773 assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med*.  
774 2020;12: eabc7075. doi:10.1126/scitranslmed.abc7075
- 775 22. Papadakis G, Pantazis AK, Ntogka M, Parasyris K, Theodosi G-I, Kaprou G, et al. 3D-printed Point-of-  
776 Care Platform for Genetic Testing of Infectious Diseases Directly in Human Samples Using Acoustic  
777 Sensors and a Smartphone. *ACS Sens*. 2019;4: 1329–1336. doi:10.1021/acssensors.9b00264
- 778 23. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)  
779 Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food

- 780 and Drug Administration Staff. Document issued on the web on May 11, 2020. Available from  
781 <https://www.fda.gov/media/135659/download>.
- 782 24. Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, et al. Rapid Molecular Detection of SARS-  
783 CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. *Infectious Diseases (except HIV/AIDS)*; 2020  
784 Feb. doi:10.1101/2020.02.26.20028373
- 785 25. Rabe BA, Cepko C. SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive  
786 protocol for sample inactivation and purification. *Proc Natl Acad Sci U S A*. 2020;117: 24450–  
787 24458. doi:10.1073/pnas.2011221117
- 788 26. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/Severe Acute  
789 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated  
790 isothermal amplification. *PloS One*. 2020;15: e0234682. doi:10.1371/journal.pone.0234682
- 791 27. Zhang Y, Ren G, Buss J, Barry AJ, Patton GC, Tanner NA. Enhancing colorimetric loop-mediated  
792 isothermal amplification speed and sensitivity with guanidine chloride. *BioTechniques*. 2020;69:  
793 178–185. doi:10.2144/btn-2020-0078
- 794 28. Broughton JP, Deng X, Yu G, Fasching CL, Singh J, Streithorst J, et al. Rapid Detection of 2019 Novel  
795 Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. *MedRxiv Prepr Serv*  
796 *Health Sci*. 2020. doi:10.1101/2020.03.06.20032334
- 797 29. Diagnostic detection of 2019-nCoV by real-time RT-PCR. -Protocol and preliminary evaluation as of  
798 Jan 17, 2020- Victor Corman et al., Available from [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2)  
799 [source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c\\_2](http://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2).
- 800 30. Detection of 2019 novel coronavirus (2019-nCoV) in suspected human cases by RT-PCR. Available  
801 from [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4)  
802 [https://www.who.int/docs/default-source/coronaviruse/peiris-](http://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4)  
[protocol-16-1-20.pdf?sfvrsn=af1aac73\\_4](http://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4).
- 803 31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated  
804 receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44: 837–845.
- 805 32. Chou P-H, Lin Y-C, Teng P-H, Chen C-L, Lee P-Y. Real-time target-specific detection of loop-  
806 mediated isothermal amplification for white spot syndrome virus using fluorescence energy  
807 transfer-based probes. *J Virol Methods*. 2011;173: 67–74. doi:10.1016/j.jviromet.2011.01.009
- 808 33. Ahn SJ, Baek YH, Lloren KKS, Choi W-S, Jeong JH, Antigua KJC, et al. Rapid and simple colorimetric  
809 detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-  
810 mediated isothermal amplification (RT-LAMP) diagnostic platform. *BMC Infect Dis*. 2019;19: 676.  
811 doi:10.1186/s12879-019-4277-8
- 812 34. Torres C, Vitalis EA, Baker BR, Gardner SN, Torres MW, Dzenitis JM. LAVA: an open-source  
813 approach to designing LAMP (loop-mediated isothermal amplification) DNA signatures. *BMC*  
814 *Bioinformatics*. 2011;12: 240. doi:10.1186/1471-2105-12-240
- 815 35. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human  
816 respiratory disease in China. *Nature*. 2020;579: 265–269. doi:10.1038/s41586-020-2008-3

- 817 36. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. *Clin*  
818 *Microbiol Rev.* 2010;23: 550–576. doi:10.1128/CMR.00074-09
- 819 37. Foo PC, Chan YY, Mohamed M, Wong WK, Nurul Najian AB, Lim BH. Development of a  
820 thermostabilised triplex LAMP assay with dry-reagent four target lateral flow dipstick for detection  
821 of *Entamoeba histolytica* and non-pathogenic *Entamoeba* spp. *Anal Chim Acta.* 2017;966: 71–80.  
822 doi:10.1016/j.aca.2017.02.019
- 823 38. Mahony J, Chong S, Bulir D, Ruyter A, Mwawasi K, Waltho D. Multiplex loop-mediated isothermal  
824 amplification (M-LAMP) assay for the detection of influenza A/H1, A/H3 and influenza B can  
825 provide a specimen-to-result diagnosis in 40 min with single genome copy sensitivity. *J Clin Virol*  
826 *Off Publ Pan Am Soc Clin Virol.* 2013;58: 127–131. doi:10.1016/j.jcv.2013.06.006
- 827 39. Dudley DM, Newman CM, Weiler AM, Ramuta MD, Shortreed CG, Heffron AS, et al. Optimizing  
828 direct RT-LAMP to detect transmissible SARS-CoV-2 from primary nasopharyngeal swab samples.  
829 Kalendar R, editor. *PLOS ONE.* 2020;15: e0244882. doi:10.1371/journal.pone.0244882
- 830 40. Henke W, Herdel K, Jung K, Schnorr D, Loening SA. Betaine improves the PCR amplification of GC-  
831 rich DNA sequences. *Nucleic Acids Res.* 1997;25: 3957–3958. doi:10.1093/nar/25.19.3957
- 832 41. Yao Y, Li Y, Liu Q, Zhou K, Zhao W, Liu S, et al. Rapid detection of hepatocellular carcinoma  
833 metastasis using reverse transcription loop-mediated isothermal amplification. *Talanta.* 2020;208:  
834 120402. doi:10.1016/j.talanta.2019.120402
- 835 42. He X, Xue F, Xu S, Wang W. Rapid and sensitive detection of Lily symptomless virus by reverse  
836 transcription loop-mediated isothermal amplification. *J Virol Methods.* 2016;238: 38–41.  
837 doi:10.1016/j.jviromet.2016.10.003
- 838 43. Garg A, Ghoshal U, Patel SS, Singh DV, Arya AK, Vasanth S, et al. Evaluation of seven commercial  
839 RT-PCR kits for COVID-19 testing in pooled clinical specimens. *J Med Virol.* 2021;93: 2281–2286.  
840 doi:10.1002/jmv.26691
- 841 44. Pearson JD, Trcka D, Lu S, Hyduk SJ, Jen M, Aynaud M-M, et al. Comparison of SARS-CoV-2 indirect  
842 and direct RT-qPCR detection methods. *Virol J.* 2021;18: 99. doi:10.1186/s12985-021-01574-4
- 843 45. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. *J Thorac*  
844 *Oncol Off Publ Int Assoc Study Lung Cancer.* 2010;5: 1315–1316.  
845 doi:10.1097/JTO.0b013e3181ec173d
- 846 46. Shatzkes K, Teferedegne B, Murata H. A simple, inexpensive method for preparing cell lysates  
847 suitable for downstream reverse transcription quantitative PCR. *Sci Rep.* 2014;4: 4659.  
848 doi:10.1038/srep04659
- 849 47. Arnaout R, Lee RA, Lee GR, Callahan C, Yen CF, Smith KP, et al. SARS-CoV2 Testing: The Limit of  
850 Detection Matters. *BioRxiv Prepr Serv Biol.* 2020. doi:10.1101/2020.06.02.131144
- 851 48. Health C for D and R. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. FDA. 2021 [cited 10  
852 Jan 2022]. Available: [https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests)  
853 [devices/sars-cov-2-viral-mutations-impact-covid-19-tests](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests)



- 854 49. MacKay MJ, Hooker AC, Afshinnekoo E, Salit M, Kelly J, Feldstein JV, et al. The COVID-19 XPRIZE  
855 and the need for scalable, fast, and widespread testing. *Nat Biotechnol.* 2020;38: 1021–1024.  
856 doi:10.1038/s41587-020-0655-4
- 857 50. World Health Organization. COVID-19 Target product profiles for priority diagnostics to support  
858 response to the COVID-19 pandemic v.1.0. Available from  
859 [https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-](https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1)  
860 [diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1](https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1) 2020.
- 861 51. Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19.  
862 *JAMA.* 2020. doi:10.1001/jama.2020.21694
- 863 52. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for  
864 Containment. *N Engl J Med.* 2020;383: e120. doi:10.1056/NEJMp2025631
- 865 53. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological  
866 assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581: 465–469.  
867 doi:10.1038/s41586-020-2196-x
- 868 54. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. *Clin Microbiol*  
869 *Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2020;26: 842–847. doi:10.1016/j.cmi.2020.04.023
- 870 55. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monné M, et al.  
871 Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis.*  
872 2021;21: 629–636. doi:10.1016/S1473-3099(20)30985-3
- 873 56. Arce A, Guzman Chavez F, Gandini C, Puig J, Matute T, Haseloff J, et al. Decentralizing Cell-Free  
874 RNA Sensing With the Use of Low-Cost Cell Extracts. *Front Bioeng Biotechnol.* 2021;9: 727584.  
875 doi:10.3389/fbioe.2021.727584

876

## 877 **Supporting information**

### 878 **S1 Fig. Primer set performance at a low copy number of SARS-CoV-2 RNA (related to Fig**

879 **1).** Primer sets for: (A) GeneN-A and GeneN-A<sup>4T</sup>; (B) N-gene and N-gene<sup>4T</sup>; (C) ORF1a-C and

880 ORF1a-C<sup>4T</sup>; (D) Gene E1<sup>4T</sup> and ORF1a<sup>4T</sup>; (E) Gene N2 and Gene N2<sup>4T</sup>; (F) As1e and ACTB<sup>4T</sup>.

881 NTC, no template control; PC, positive control (30 copies of SARS-CoV-2 RNA); TTR, time to

882 results (min); Error bars represent mean ± standard deviations.

883 **S2 Fig. Fluorescence plots and end-point color changes for LoD and specificity assays**  
884 **(related to Fig 2).** Fluorescent readouts and images of color changes at 60 minutes are shown for  
885 the following primer sets: (A) Gene E1. (B) N-gene. (C) Gene N2. (D) ORF1a. (E) ACTB.  
886 Primer amounts (F3B3/FIPBIP/LFBBF,  $\mu\text{M}$ ) are indicated above each assay. Each condition was  
887 evaluated with 10 replicates. RFU, relative fluorescence units; NTC, no template control.

888 **S3 Fig. Effect of primer set multiplexing and guanidine hydrochloride and betaine**  
889 **supplements (related to Fig 3).** (A) Fluorescent readouts of RT-LAMP with the indicated  
890 primer multiplexing (also see Fig3A). (B) Phenol red colour at 60 minutes from assays in (A).  
891 (C) Fluorescent readouts of RT-LAMP with multiplexed primer sets for Gene E1 and ORF1a  
892 with the indicated supplements (also see Fig3B). (D) Phenol red colour at 60 minutes from  
893 assays in (C). RT-LAMP reactions were performed with 15 copies of SARS-Cov-2 RNA, and  
894 each condition was evaluated with 10 replicates. NTC, no template control; RFU, relative  
895 fluorescence units.


896 **S4 Fig. End-point color changes for RT-LAMP reactions with extracted clinical RNA**  
897 **compared to Ct values for RT-PCR (related to Fig 4).** (A) Phenol red colour of RT-LAMP  
898 assays with extracted RNA from clinical NP samples. RT-LAMP was carried out in a water  
899 batch at  $65^{\circ}\text{C}$  for 25 minutes with multiplexed Gene E1 and ORF1a primers and 40mM and  
900 0.5M betaine. (B) Sensitivity and specificity in (A). NTC, no template control; PC, positive  
901 control (240 copies of SARS-CoV-2 and 1ng human RNA).

902 **S5 Fig. ACTB detection using the direct RT-LAMP method without RNA extraction**  
903 **(related to Fig 5).** (A) Distribution of ACTB TTRs of raw clinical NP samples under the

904 indicated RT-LAMP conditions. (B) Distribution of ACTB TTRs between RT-LAMP test  
905 positive and negative from contrived raw positive NP samples.

906 **S6 Fig. Optimization of SYTO 9 concentration for direct RT-LAMP with FluoroPLUM**  
907 **(related to Fig 7).** RT-LAMP for ACTB was performed with 10 clinical NP samples with the  
908 indicated SYTO 9 concentrations. Bars represented the mean slope<sub>20-40</sub>. A paired t-test was used  
909 to assess differences in the means. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

**Fig 1**



**Fig 2**

**A**

SARS-CoV2 primers


Primers	F3B3/FIPBIP/LFLB ( $\mu$ M)	Sensitivity (Copies)				LoD	Specificity (Min)	
		30	60	120	240		45	60
<b>ORF1a</b>	<b>0.2/3.2/0.4</b>	<b>4/10</b>	<b>9/10</b>	<b>10/10</b>	<b>10/10</b>	<b>120</b>	<b>10/10</b>	<b>6/10</b>
	0.2/1.6/0.4	3/10	5/10	8/10	10/10	240	9/10	6/10
<b>Gene E1</b>	<b>0.2/3.2/0.4</b>	<b>4/10</b>	<b>9/10</b>	<b>9/10</b>	<b>10/10</b>	<b>240</b>	<b>10/10</b>	<b>10/10</b>
	0.2/1.6/0.8	3/10	6/10	9/10	10/10	240	10/10	7/10
<b>Gene N2</b>	<b>0.2/3.2/0.4</b>	<b>2/10</b>	<b>4/10</b>	<b>8/10</b>	<b>10/10</b>	<b>240</b>	<b>10/10</b>	<b>10/10</b>
	0.2/1.6/0.8	6/10	6/10	9/10	10/10	240	9/10	7/10
<b>N-gene</b>	<b>0.4/3.2/0.8</b>	<b>4/10</b>	<b>7/10</b>	<b>9/10</b>	<b>10/10</b>	<b>240</b>	<b>10/10</b>	<b>8/10</b>
	0.4/6.4/0.8	2/10	6/10	9/10	10/10	240	7/10	1/10

**B**

ACTB primers


Primer	F3B3/FIPBIP/LFLB ( $\mu$ M)	Sensitivity (ng)	Sensitivity				LoD	Specificity (Min)	
			0.01	0.05	0.25	1.25		45	60
<b>ACTB</b>	<b>0.05/0.4/0.1</b>	<b>10/10</b>	<b>10/10</b>	<b>10/10</b>	<b>10/10</b>	<b>&lt;0.01</b>	<b>10/10</b>	<b>10/10</b>	
	0.05/0.8/0.2	10/10	10/10	10/10	10/10	<0.01	8/10	8/10	

**Fig 3**




**C** LoD assessment of optimized RT-LAMP





Primers	Supplements	Sensitivity (Copies)	Sensitivity				LoD
			7.5	15	20	25	
Gene E1 + ORF1a	40 mM GuHCl + 0.5 M Betaine	4/10	9/10	10/10	10/10	20	



**Fig 4**




**Fig 5**







**Fig 6**




**Fig 7**




S1 Fig




# S2 Fig




A




B



C



D



# S4 Fig

A

Samples	N1	N2	N3	N4	N5	N6	N7	N8	N9	N10	P1	P2	P3	P4	P7	P9	P10	NTC	NTC	PC
Ct <sup>ORF1ab</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	29.1	25.3	30.3	29.1	24.8	36.2	32.9	N/A	N/A	N/A
Ct <sup>ACTB</sup>	28.6	30.7	28.6	27.5	26.3	29.7	30.5	28.8	31.6	30.6	27.1	26.0	31.9	26.3	26.2	27.1	32.1	N/A	N/A	N/A



Samples	N11	N12	N13	N14	N15	P11	P12	P13	P14	P15	N16	N17	N18	N19	N20	N21	P16	P18	P19	P20
Ct <sup>ORF1ab</sup>	N/A	N/A	N/A	N/A	N/A	24.8	32.5	32.8	19.0	27.1	N/A	N/A	N/A	N/A	N/A	N/A	36.9	18.0	33.1	20.5
Ct <sup>ACTB</sup>	27.1	32.5	27.2	25.9	26.7	26.6	26.6	27.1	28.2	27.3	26.3	26.3	28.9	29.3	26.2	27.1	28.4	29.2	31.3	27.1



Samples	N22	N23	N24	N25	N26	N27	N28	N29	N30	P21	P23	P24	P25	P26	P27	P28	P29	P30	P31
Ct <sup>ORF1ab</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	31.6	22.4	24.6	20.1	21.2	30.0	24.8	24.7	30.2	28.5
Ct <sup>ACTB</sup>	28.2	26.2	27.1	25.9	30.2	27.4	28.1	27.9	26.2	26.5	26.1	27.8	26.7	25.7	31.7	27.4	28.4	29.2	29.3




Samples	N31	N32	N33	N34	N35	N36	P32	P34	P35	P36	NTC	NTC	PC
Ct <sup>ORF1ab</sup>	N/A	N/A	N/A	N/A	N/A	N/A	36.2	21.2	22.6	22.4	N/A	N/A	N/A
Ct <sup>ACTB</sup>	28.2	26.2	27.1	25.9	30.2	27.4	26.2	27.1	28.1	26.2	N/A	N/A	N/A



B

Sensitivity = 28/30 = 93.3%
Specificity = 36/36 = 100%

# S5 Fig



S6 Fig

